

# Christopher

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4645136/christopher-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72  
papers

1,146  
citations

19  
h-index

31  
g-index

93  
ext. papers

1,644  
ext. citations

5.1  
avg, IF

4.41  
L-index

#	Paper	IF	Citations
72	Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort.. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2022</b> , 5, 39-47	0.5	2
71	Review article: Therapeutic targets for the pharmacologic management of coeliac disease-The future beyond a gluten-free diet.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	0
70	Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 873-886	6.1	6
69	Clinical, endoscopic and safety placebo rates in induction and maintenance trials of Crohn's disease: Meta-analysis of Randomised controlled trials. <i>Journal of Crohn's and Colitis</i> , <b>2021</b> ,	1.5	1
68	Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis. <i>American Journal of Gastroenterology</i> , <b>2021</b> ,	0.7	1
67	Epidemiology and Natural History of Perianal Crohn's Disease: A Systematic Review and Meta-Analysis of Population-Based Cohorts. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	1
66	Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> ,	4.5	1
65	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> , 19, 2064-2071.e1	6.9	2
64	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 1	4	0
63	Methods for handling missing segments in Crohn's disease clinical trials: analysis from the EXTEND trial. <i>Gut</i> , <b>2021</b> ,	19.2	
62	Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators. <i>Inflammatory Bowel Diseases</i> , <b>2021</b> , 27, e98	4.5	0
61	An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. <i>Gastroenterology</i> , <b>2021</b> , 160, 2291-2302	13.3	10
60	Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis. <i>Gastroenterology</i> , <b>2021</b> , 160, 88-98.e4	13.3	12
59	An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 784-793	6.1	3
58	Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. <i>Drugs</i> , <b>2021</b> , 81, 333-347	7.1	4
57	Population-based Trends in Healthcare Utilization and National Healthcare Spending on Pancreatitis in North America. <i>Gastroenterology</i> , <b>2021</b> , 161, 1698-1701.e5	13.3	0
56	Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study. <i>Gut</i> , <b>2021</b> ,	19.2	4

55	Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): An International Multidisciplinary Consensus. <i>Gastroenterology</i> , <b>2021</b> , 161, 748-755	13.3	1
54	A Summary of the Meetings of the Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS) International Multidisciplinary Consensus. <i>Gastroenterology</i> , <b>2021</b> , 161, 778-784	13.3	
53	An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1108-1117	6.1	2
52	Systematic review: medical therapy for fibrostenosing Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1233-1246	6.1	11
51	Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment. <i>PLoS ONE</i> , <b>2020</b> , 15, e0227635	3.7	11
50	Vedolizumab Induced Clinical, Endoscopic, and Histological Improvement in Common Variable Immunodeficiency Disease-associated Intestinal Enteropathy. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, e22-e23	4.5	3
49	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005-2016). <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2500-2509.e1	6.9	8
48	Safety of Combination Biologic and Antirejection Therapy Post-Liver Transplantation in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 949-959	4.5	3
47	Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , <b>2020</b> , 26, 515-523	4.5	4
46	Is there room for immunomodulators in ulcerative colitis?. <i>Expert Opinion on Biological Therapy</i> , <b>2020</b> , 20, 379-390	5.4	2
45	Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 435-445	6.1	11
44	The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2020</b> , 3, 234-242	0.5	9
43	Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions. <i>Current Treatment Options in Gastroenterology</i> , <b>2020</b> , 18, 442-461	2.5	1
42	Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 2139-2141.e2	6.9	6
41	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1760-1768.e1	6.9	7
40	Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 51, 1047-1066	6.1	10
39	Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 5-23	6.1	43
38	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <i>Colorectal Disease</i> , <b>2019</b> , 21, 1279-1287	2.1	4

37	Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Journal of Crohn's and Colitis</i> , <b>2019</b> , 13, 1201-1216	1.5	9
36	Teduglutide in Patients With Active Crohn's Disease and Short Bowel Syndrome. <i>Inflammatory Bowel Diseases</i> , <b>2019</b> , 25, e109	4.5	5
35	Targeting anti-fibrotic pathways in Crohn's disease - The final frontier?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2019</b> , 38-39, 101603	2.5	6
34	IL12/23 or selective IL23 inhibition for the management of moderate-to-severe Crohn's disease?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2019</b> , 38-39, 101604	2.5	16
33	What is the role of C-reactive protein and fecal calprotectin in evaluating Crohn's disease activity?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2019</b> , 38-39, 101602	2.5	11
32	Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2374-2376.e2	6.9	11
31	Innovations in Oral Therapies for Inflammatory Bowel Disease. <i>Drugs</i> , <b>2019</b> , 79, 1321-1335	12.1	30
30	Improving Clinical Trial Efficiency in Gastroenterology. <i>Gastroenterology</i> , <b>2019</b> , 157, 892-893	13.3	5
29	Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 364-374	6.1	1
28	Identifying Outcomes in Clinical Trials of Fistulizing Crohn's Disease for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1904-1908	6.9	6
27	Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1515-1524.e4	6.9	12
26	Identifying Outcomes in Clinical Trials of Pouchitis for the Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 1637-1640	6.9	0
25	Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1578-1596	6.1	19
24	Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1407-1419.e22	6.9	29
23	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 637-647.e13	6.9	27
22	Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 649-660	5.9	13
21	Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , <b>2018</b> , 63, 2555-2563	4	6
20	Clinical utility of ustekinumab in Crohn's disease. <i>Journal of Inflammation Research</i> , <b>2018</b> , 11, 35-47	4.8	23

19	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , <b>2018</b> , 16, 1714-1729.e3	6.9	18
18	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2018</b> , 1, 115-123	0.5	21
17	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 114-126	6.1	7
16	Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1232-1243	6.1	101
15	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. <i>BMJ Open</i> , <b>2017</b> , 7, e016146	3	26
14	Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 833-839	4.5	59
13	Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2017</b> , 23, 1643-1649	4.5	28
12	Surgical Rates for Crohn's Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study. <i>American Journal of Gastroenterology</i> , <b>2017</b> , 112, 1840-1848	0.7	91
11	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 870-9	4.5	48
10	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 5315798	2.8	6
9	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 2016, 2079582	2.8	12
8	Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. <i>Journal of Clinical Gastroenterology</i> , <b>2015</b> , 49, 675-82	3	27
7	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 1454-63	1.5	37
6	Colonic Dieulafoy's Lesion: A Rare Cause of Lower Gastrointestinal Hemorrhage and Review of Endoscopic Management. <i>Case Reports in Gastrointestinal Medicine</i> , <b>2014</b> , 2014, 436293	0.6	6
5	Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1044-55	6.1	32
4	Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 3347-51	5.6	24
3	Postoperative complications and mortality following colectomy for ulcerative colitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 972-80	6.9	130
2	Inflammatory bowel disease patients who leave hospital against medical advice: predictors and temporal trends. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 845-51	4.5	22

- 1 Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. *Alimentary Pharmacology and Therapeutics*, **2009**, 30, 977-86 6.1 37